Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.

Insulet (PODD) on Tuesday priced a private placement of $450M aggregate principal amount of senior unsecured notes due 2033, for net proceeds of about $444.4M.

Insulet (NASDAQ:PODD – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday. Several other equities analysts ...

Shares of Insulet Corp. PODD slid 5.93% to $266.68 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.37% ...

Independent Advisor Alliance grew its position in Insulet Co. (NASDAQ:PODD – Free Report) by 20.8% in the 4th quarter, ...

Below is Validea's guru fundamental report for INSULET CORP (PODD). Of the 22 guru strategies we follow, PODD rates highest using our Twin Momentum Investor model based on the published strategy ...

Click here to discover the nuances of Insulet with our detailed analytical report. NasdaqGS:PODD Revenue & Expenses Breakdown as at Mar 2025 Insulet (NasdaqGS:PODD) has rewarded its shareholders ...